Evidence map›Paper›PMID 29963769›Full record

ArticleCancer medicine2018

Evaluation of CHK1 activation in vulvar squamous cell carcinoma and its potential as a therapeutic target in vitro.

Zhihui Wang, Mette S Førsund, Claes G Trope, Jahn M Nesland, Ruth Holm, Ana Slipicevic

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zhihui WangDepartment of Pathology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Mette S FørsundDepartment of Pathology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Claes G TropeDepartment of Obstetrics and Gynecology, The Norwegian Radium Hospital, Oslo University Hospital and University of Oslo, Oslo, Norway.
Jahn M NeslandDepartment of Pathology, The Norwegian Radium Hospital, Oslo University Hospital and University of Oslo, Oslo, Norway.
Ruth HolmDepartment of Pathology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Ana SlipicevicDepartment of Pathology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.ORCID 0000-0001-9770-2305

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CHK1 is an important regulator of the cell cycle and DNA damage response, and its altered expression has been identified in various tumors. Chk1 inhibitors are currently being evaluated as monotherapy and as potentiators of chemotherapy in clinical settings. However, to our knowledge, no previous study has investigated either the activation status or the therapeutic potential of CHK1 targeting in vulvar cancer. Therefore, we examined the expression status of activated CHK1 forms pCHK1

Indexed as

Transcriptional ActivationAdultAgedAged, 80 and overApoptosisBiomarkers, TumorCarcinoma, Squamous CellCell CycleCell Line, TumorCheckpoint Kinase 1DNA DamageFemaleHumansImmunohistochemistryKaplan-Meier EstimateMiddle AgedBiomarkers, TumorCheckpoint Kinase 1CHEK1 protein, humanProtein Kinase InhibitorsRNA, Small InterferingCheckpoint kinase 1Chk1 inhibitorimmunohistochemistryprognosissiRNAvulvar squamous cell carcinomas

Identifiers

PMID29963769
PMCPMC6089182

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.